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Parkinson's diseaseParkinson's disease is a progressive neurodegenerative disease in the elderly, and no cure or disease-modifying
therapies exist. Several lines of evidence suggest that mitochondrial dysfunction and oxidative stress have a cen-
tral role in the dopaminergic neurodegeneration of Parkinson's disease. In this context, mitochondria-targeted
therapies that improve mitochondrial function may have great promise in the prevention and treatment of
Parkinson's disease. In this review, we discuss the recent developments in mitochondria-targeted antioxidants
and their potential beneﬁcial effects as a therapy for ameliorating mitochondrial dysfunction in Parkinson's dis-
ease. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurode-
generative Diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is a progressive neurodegenerative dis-
order that affects more than 1 million individuals over the age of
60 years in the United States [1]. According to a recent article, about
50,000 new cases are diagnosed annually, and this ﬁgure is expected
to increase substantially as the median age of the population continues
to rise in the coming decades [2]. Epidemiological studies suggest that
sporadic late-onset PD accounts for 90% of cases, whereas the remaining
10% are early onset cases that mainly occur in familial clusters [3,4].
Pathologically, PD is characterized by the loss of dopaminergic neurons
within the substantia nigra pars compacta (SNc) and the ensuingnt; PD, Parkinson's disease; SNc,
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ights reserved.depletion of dopamine in the striatum. This loss of dopaminergic neu-
rons causes most of the motor symptoms of PD. By the time PD motor
symptoms are clinically recognized, 60% of dopaminergic neurons and
80% of putamen dopamine have been lost [5]. PD is also associated
with the presence of ubiquitin- and α-synuclein-positive cytoplasmic
inclusions known as Lewy bodies within surviving dopaminergic neu-
rons [6]. In addition to the nigrostriatal dopaminergic defects, emerging
clinical evidence suggests that extranigral degeneration and non-motor
symptoms are key features of early stages of PD pathogenesis [7–10].
Currently, the available therapies for PD only treat the symptoms;
none slowor prevent progressive neuronal degeneration in the dopami-
nergic system [11,12]. Dopamine replacement therapy, i.e., levodopa
administered orally or stimulation of dopamine receptors, has been
themost widely used treatment option for PD, but the beneﬁcial effects
of dopaminergic therapy wear off over time and its clinical efﬁcacy
gradually declines as the disease advances [13].
Despite extensive research, the precise cause of sporadic PD or non-
familial PD remains unknown, but several pathogenicmechanisms have
been proposed, including oxidative stress, mitochondrial dysfunction,
impairment of the ubiquitin-proteasome system, and neuroinﬂam-
mation. Convincing evidence from postmortem brain tissue, cell culture
and animal models of PD and the analysis of human genetics support
the involvement of oxidative stress and mitochondrial dysfunction in
PD pathogenesis [14,15]. Mitochondrial dysfunction due to oxidative
stress, mitochondrial DNA deletions, alteredmitochondrialmorphology
and the interaction of pathogenic proteins with mitochondria all result
in dopaminergic neurodegeneration. Thus, therapeutic approaches
targeting mitochondrial dysfunction and related oxidative stress may
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rating complications arising from PD is to suppress mitochondrial re-
active oxygen species (ROS) generation with speciﬁc antioxidants.
Several small antioxidant molecules, such as ubiquinol and creatine,
have shown promising neuroprotective effects in different models of
PD [16,17]. However, a major limitation of using these compounds to
treat PD is their failure to accumulate preferentially in the target organ-
elle mitochondria. For this reason, several strategies to identify antioxi-
dants with therapeutic potential that speciﬁcally target mitochondria
have been developed. In this review, we will describe cellular changes
in the progression of PD, and in our discussion of promising PD thera-
peutic strategies, we will focus on the mitochondrially targeted antiox-
idants as potential therapies for PD.
2. Production of mitochondrial ROS
Mitochondria play a central role in the life and death of cells. Physi-
ologically, mitochondria perform a variety of fundamental regulatory
processes in the cell, including ATP production [18], calcium homeosta-
sis and modulation [19], amino acid and nitrogen metabolism [20], ap-
optotic cell death [21], ROS generation and detoxiﬁcation [22,23], and
heme and iron–sulfur center biosynthesis [24]. They supply the vast
majority of cellular energy in the form of ATP through oxidative phos-
phorylation. During oxidative phosphorylation, electrons from reduced
cofactors are transferred through a series of respiratory chain com-
plexes (complexes I–IV) located in the mitochondrial inner membrane
to oxygen, the ultimate electron acceptor. The ﬂow of electrons simulta-
neously leads to the pumping of protons out of the mitochondrial
matrix. This electrochemical reaction generates a transmembrane po-
tential (ΔΨm)yielding the energy for ATP synthesis fromADP and inor-
ganic phosphate.
ROS can be generated within mitochondria in several sites of mito-
chondrial electron transport chains (ETC), in particular on complexes I
and III, where electrons occasionally leak to oxygen and forma superox-
ide anion (O2•−), the predominant ROS inmitochondria (Fig. 1) [25,26].
In fact, mitochondria are the major sites of cellular ROS production,
with approximately 1–3% of mitochondrial oxygen consumption beingFig. 1. Schematic presentation of the generation of ROS in mitochondria. ROS are generated from
tochondrial electron transport chain complexes I and III. Once generated, superoxide is decomp
SOD2 (MnSOD) in the matrix to form hydrogen peroxide, which is further catabolized to wa
thioredoxin reductase (TPx) to avoid possible buildup of oxidative stress. However, under mit
nitrating agent peroxynitrite (ONOO−). Hydrogen peroxide can also form the highly reactive h
cause damage to proteins, lipids, and nucleic acids. CoQ, coenzyme Q; Cyt C, cytochrome C.converted to ROS [27]. In addition to formation from incomplete re-
duction of oxygen in ETC, a number of enzyme systems also generate
superoxide, including the tricarboxylic acid cycle (TCA) enzymes α-
ketoglutarate dehydrogenase [28] and aconitase [29], the non-TCA
cycle enzymes pyruvate dehydrogenase, dihydroorotate dehydroge-
nase [30] and glycerol-3-phosphate dehydrogenase [31], and the mito-
chondrial outer membrane proteins such as methemoglobin reductase
[32]. Because of its negative charge and poor membrane permeabil-
ity, superoxide is relatively unreactive, but it can react rapidly with
nitric oxide (NO) to form the potent oxidant and nitrating agent
peroxynitrite (ONOO−) and subsequently other reactive nitrogen spe-
cies (RNS). Moreover, it is able to damage some mitochondrial iron–
sulfur cluster-containing proteins [33]. Most cellular superoxide is
rapidly converted to hydrogen peroxide (H2O2) either through sponta-
neous dismutation or dismutation reactions catalyzed by superoxide
dismutase (SOD) [34]. Hydrogen peroxide itself is a reactive free radical
that is stable, membrane permeable and has a relatively long half-life
enabling diffusion within the cell. As a redox active species, H2O2 can
inactivate some enzymes by oxidizing their thiol groups [35], although
it is unable to oxidize DNA or lipids directly [33]. Hydrogen peroxide
can be decomposed by cytosolic andmitochondrial antioxidant systems
such as glutathione peroxidase (GPx), catalase (CAT), and thioredoxin
reductase (TPx). However, if not removed, it can further produce the
highly reactive hydroxyl radical (OH•) in the presence of Fe2+ cations
via the Fenton reaction [36]. The OH• has a strong oxidizing poten-
tial and can damage virtually every type of macromolecule close to
their site of origin, making it an extremely dangerous compound to
the organism. Furthermore, unlike superoxide and hydrogen peroxide,
which can be detoxiﬁed by an enzymatic conversion, no enzymatic
routes are known for eliminating hydroxyl radicals. Nonenzymatic
mechanisms for scavenging peroxyl radicals include several antioxi-
dants such as vitamin E and glutathione. Other radicals derived fromox-
ygen include peroxyl radical (RO2•), hypochlorous acid (HOCl), alkoxyl
radical (RO•), and hydroperoxyl radical (HO2•), which are high-energy
species and exhibit a broad array of biological actions. Additional endog-
enous sources of cellular ROS are macrophages, neutrophils, and eosin-
ophils. ROS generation can also occur through a host of exogenousthe transfer of electrons (e−) to molecular oxygen to form superoxide (O2•−) at themi-
osed enzymatically by superoxide dismutase 1 (SOD1) in the intermembrane space and by
ter by the action of enzymes such as catalase (CAT), glutathione peroxidases (GPx), and
ochondrial stress, superoxide may react with nitric oxide to form the potent oxidant and
ydroxyl radical (OH•) in the presence of Fe2+ cations. These highly reactive radicals may
1284 H. Jin et al. / Biochimica et Biophysica Acta 1842 (2014) 1282–1294sources including ultraviolet and high-energy irradiation, redox-cycling
of quinones, xenobiotics, ions, metals, aging, and environmental toxins
[37–41].
It is worth pointing out that ROS production can be signiﬁcant in
both physiological and pathological situations depending on the envi-
ronment. For example, it has been demonstrated that at lower physio-
logical levels, mitochondrially generated H2O2 acts as an intracellular
signaling molecule, affecting multiple cellular functions [42–44]. Thus,
it is possible that an overuse of antioxidantsmay be detrimental. In con-
trast, at high concentrations, ROS may cause extensive damage to cells
and thewhole organism, consisting of the peroxidation of lipids, partic-
ularly phospholipids of biological membranes, the carbonylation of pro-
teins, or oxidative damage to mtDNA [23,26,36,45]. These noxious
actions, often referred to as “oxidative stress”, either individually or col-
lectively can disrupt mitochondrial function and cause ROS to ﬂow to
the cytosol,which in turn results in a further increase inROS production,
thus forming a vicious cycle [46]. In this sense, mitochondria are be-
lieved to have developed an excessive network of antioxidant defenses.
Therefore, a delicate balance between ROS and antioxidants within mi-
tochondria is essential for the functions of cells, tissues, and organs.
3. Scavenging of mitochondrial ROS
Mitochondria contain a series of well-deﬁned and tightly controlled
antioxidant defense systems, which work synergistically to intercept
ROS, therebyminimizing oxidative damage. Disruption of these antiox-
idant defenses may result in extensive oxidative damage to mitochon-
dria. There are two main types of mitochondrial antioxidant defense
systems: enzymatic and nonenzymatic. Enzymatic antioxidants involve
SOD, GPx, catalase, and TPx, all of which are encoded by the nuclear ge-
nome and are subsequently imported into themitochondria. SOD is one
of the most effective intracellular enzymatic antioxidants, and as men-
tioned in the previous section, SOD catalyzes the dismutation of super-
oxide into oxygen and hydrogen peroxide. In mammals, three forms of
SOD exist depending on the nature of the active metal center. SOD1 or
Cu/Zn SODbinds copper and zinc and is a cytoplasmic andmitochondri-
al inter-membrane space protein [47]. SOD2 (Mn-SOD) has manganese
ion at its reactive center and is only expressed in the mitochondrial
matrix, and SOD3 is secreted into the extracellular space after its protein
translation [48]. Mn-SOD null mice die shortly after birth, conﬁrming
the importance of keeping superoxide in check in mammals [49]. GPx
mainly detoxiﬁes free H2O2 and lipid peroxides using reduced glutathi-
one (GSH) as a cofactor. In this process, GSH is converted to its oxidized
form, glutathione disulﬁde (GSSG). Once oxidized, GSH can be regen-
erated by the action of glutathione reductase using NADPH as its elec-
tron donor. In addition, GSH serves as a nonenzymatic antioxidant,
scavenging hydroxyl radical and singlet oxygen directly and maintain-
ing vitamins C and E in their reduced forms.
Other nonenzymatic antioxidants include α-tocopherol (vitamin E),
ascorbic acid (vitamin C), coenzyme Q10 (CoQ10), β-carotene, ﬂavonoids,
and α-lipid acid [50]. Vitamin E is lipid-soluble, and therefore, is widely
distributed in mammalian cell membranes. Of the different forms of
vitamin E, α-tocopherol is the most biologically active form. As a lipid-
soluble antioxidant, vitamin E acts as a scavenger of peroxyl radical,
peroxynitrite, and hydroxyl radical by preventing the propagation of
the radical chain, thus effectively inhibiting lipid peroxidation. During
the antioxidant reaction, α-tocopherol is converted to α-tocopherol
radical, which gets reduced to its original α-tocopherol form. Another
vitamin antioxidant is vitamin C, which is water-soluble, making it able
to work in the body's aqueous environments. Vitamin C functions in as-
sociation with vitamin E to regenerate α-tocopherol from α-tocopherol
radical. CoQ10 is an essential component of the ETC, where it accepts
electrons from complexes I and II. It is also a coenzyme for complex III
and acts as a lipid-soluble antioxidant as well. The antioxidant activ-
ity of CoQ10 arises from its capacity to exchange two electrons in a
redox cycle between its oxidized (ubiquinone) and its reduced form(ubiquinol). Ubiquinol is a very effective chain-breaking antioxidant
that not only inhibits lipid peroxidation and protein and DNA oxidation,
but also directly quenches oxidants such as superoxide and peroxyl
radicals.
Despite the presence of elaborate defense systems to counteract
oxidative damage, it seems that cellular ROS levels are not perfectly
under control. Indeed, oxidative damage due to excessive ROS produc-
tion may accumulate during both normal and stressful conditions. Oxi-
dative stress accumulation and concomitant mitochondrial dysfunction
have been implicated in PD pathogenesis.
4. Oxidative stress in PD
Oxidative stress has long been implicated in the process of neuro-
degeneration in PD pathogenesis. Oxidative stress, arising from exces-
sive production of ROS and/or defective ROS removal, can potentially
damage cellular lipids, proteins, and DNA. Postmortem studies have
consistently shown high levels of oxidation of lipids, proteins, and
nucleic acids in the SNc of sporadic PD brains [51–56]. Also, signiﬁcant
alterations of the antioxidant defense system, in particular reduced
glutathione, were found in the SNc of PD patients [57]. As mentioned
above, ETC is the major source of ROS, in particular the hydrogen per-
oxide and superoxide anions [58]. In the presence of ferrous iron,
these ROS can be converted to even more potent ROS, such as the hy-
droxyl radical and hydroxyl anion [59,60]. Not surprisingly, the level
of iron was signiﬁcantly increased in the SNc of PD brains [61–64].
Apart from being the main source of increased oxidative stress in PD
brains, mitochondrial function itself can be affected by oxidative stress
[26,65,66], which further contributes to the accumulation of ROS and
mitochondrial damage in a vicious cycle. This feed-forward mechanism
is what commonly underlies neuronal cell death in neurodegenerative
diseases. In addition to mitochondria, the auto-oxidation of dopamine,
a reaction known to generate superoxide and hydrogen peroxide, as
well as reactive dopamine quinones, speciﬁcally contribute to cellular
ROS in dopaminergic neurons [67,68]. This dopamine-dependent oxida-
tive stress is believed to partially explain the selective vulnerability of
dopaminergic neurons in PD. Another important contributor to oxida-
tive stress is NO, which is generated by nitric oxide synthase (NOS)
[52]. The reaction of ROS with NO produces highly toxic RNS, such as
the peroxynitrite and nitro-tyrosyl radicals [69]. Besides damaging cel-
lular proteins, lipids, and DNA, oxidative stress also activates a variety
of cell death pathways [70–79].
5. Mitochondrial dysfunction in PD
Considerable evidence exists suggesting a role for mitochondrial
dysfunction in PD pathogenesis [38,80]. Mutations in mitochondrial
DNA (mtDNA) play a role in the demise of dopaminergic neurons. In-
deed, high levels of somatic mtDNA point mutations in elderly PD pa-
tients have also been reported [81]. However, the most deﬁnitive
evidence of mitochondrial dysfunction in PD has come from studies
using MPTP, a Parkinsonian toxicant which causes Parkinsonian syn-
dromes in humans, rodents and primates by inhibiting themitochondri-
al complex-I of the electron transport chain [82]. Similar toMPTP, other
complex-I inhibitors such as rotenone, maneb, paraquat, fenzaquin and
trichloroethylene result in the loss of nigral dopaminergic neurons in
the mouse model of PD, implicating mitochondrial dysfunction in its
pathogenesis [83,84]. Additionally, impairment of complex-I activity
has been reported in the substantia nigra, platelets and skeletal muscles
of PD patients [85,86]. Moreover, reduced complex-I activity and an in-
creased susceptibility to MPP+, the toxic metabolite of MPTP, were also
observed inmitochondrial DNA fromPDpatients, clearly demonstrating
mtDNA-encoded defects in PD [87,88].
Recently, more convincing evidence of mitochondrial dysfunction in
PD has been reported in conditional knockout ‘MitoPark’ mice, which
have a disrupted mitochondrial transcription factor A (Tfam) gene in
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sion, attenuated expression of respiratory chain function in dopaminer-
gic neurons in nigra along with behavioral impairments and striatal
dopamine depletion, mimicking progressive PD phenotypes starting
from 18 weeks of age [89].
Pathogenic mutations in several genes including α-synuclein,
LRRK2, parkin, DJ-1 and PINK-1 also play an important role inmitochon-
drial dysfunction in PD patients [2,90]. Impairedmitochondrial function
in the MPTP mouse model of PD has been reported in cells over-
expressing α-synuclein and in transgenic mice [91,92]. Based on all
these ﬁndings, it can be inferred that intervening in one or more of
these processes could alleviate the harmful effects of mitochondrial
dysfunction.
6. Antioxidant therapy
Since PD is a complex, multifactorial disease with oxidative stress
and mitochondrial dysfunction playing central roles in nigrostriatal do-
paminergic neurodegeneration, antioxidants targeting these factors
have become attractive therapeutic agents in the treatment of PD. In
this section, we will summarize the current evidence for preventing or
slowing the development of PD by neuroprotective antioxidant agents.
6.1. Vitamin antioxidants
Various forms of vitamin antioxidants (Fig. 2A–B) have been tested
for their neuroprotective potential. Vitamin E deﬁciency increased
MPTP-induced dopaminergic neurotoxicity [93]. In another study, re-
searchers found that administering vitamin E ameliorated oxidative
stress induced by iron accumulation in themouse brain [94], suggesting
that vitamin Emay be neuroprotective against PD. Additionally, vitamin
E was neuroprotective in 6-OHDA-treated animals [95]. The observa-
tional data in humans suggest that the combined administration of
high-dose vitamin E and vitamin C supplements was associated with aFig. 2. Structures of a series of small-molecule antioxidants showing protection in PD models, i
(G) diapocynin.reduced progression of PD [96]. However, the results of double-blind,
randomized controlled trials have been disappointing, where vitamin
E showed no beneﬁts in PD [97,98]. More recently, a large cohort
study demonstrated that high dietary vitamin E intake, but not vitamin
C or carotenoids, reduced the risk of PD [99]. But in contrast, other stud-
ies contradict results regarding food intake of vitamin E and its efﬁcacy
to prevent PD progression [100–102]. The protective role of vitamin C in
PD remains controversial since one epidemiological study found a de-
creased risk of PD in individuals consuming diets rich in vitamin C,
whereas other studies showed no effects or even an increased risk of
PD with consumption of vitamin C [99,100,103].
6.2. Creatine
Creatine (Fig. 2C) is a nitrogenous guanidine compound that forms
high energy phosphate bonds, occurs naturally in vertebrates and sup-
plies energy to muscle and nerve cells. Creatine also possesses antioxi-
dant properties and can be an effective inhibitor of mitochondrial
permeability transition pore opening andmitochondrial iron accumula-
tion. Preclinical studies in various models have demonstrated its poten-
tial role as a neuroprotective agent [104]. Recently, a neuroprotective
effect of creatine was demonstrated in MPP+ and 6-OHDA-treated do-
paminergic neuronal cell cultures, where it protected tyrosine hydroxy-
lase immunoreactive dopaminergic neurons and their ﬁbers [105]. In
the MPTP mouse model of PD, creatine restored the MPTP-induced
loss of dopamine and protected dopaminergic neurons [106]. In early
clinical studies, 2 g daily creatine administration improved behavioral
difﬁculties in a clinical trial of 200 subjects who were within 5 years
of a PD diagnosis [16]. In an additional follow-up study, creatine contin-
ued to showneuroprotective efﬁcacy 18 months after creatine adminis-
tration [107]. Although a 2-year placebo-controlled study of 60 subjects
demonstrated that creatine had no effect on PD scores or dopamine
transporter imaging, improved mood behavior (a non-motor symptom
of PD) was noticed in those patients [108]. Recently, a phase III clinicalncluding (A) vitamin E, (B) vitamin C, (C) creatine, (D) CoQ10, (E) urate, (F) apocynin, and
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dose of 10 g in a large long-term study of PD targeting 1720 participants
with the disease [109,110]. This study involving 52 medical facilities is
expected to be completed in 5–7 years.
6.3. CoQ10
CoQ10 also shows promise as a neuroprotective agent in PD (Fig. 2D).
Postmortem studies have shown that CoQ10 levels in the plasma and
platelets of PD patients were signiﬁcantly lower compared to age-
matched controls, and that the oxidized form of CoQ10 was elevated in
PD patients, suggesting that taking CoQ10 supplements may be beneﬁ-
cial. Neuroprotective properties of CoQ10 have since been demonstrat-
ed in various in vivo and in vitro models of PD. More speciﬁcally,
paraquat- and rotenone-inducedmitochondrial dysfunction and neuro-
degeneration in rat mesencephalic primary neurons were inhibited by
CoQ10 [111]. Also, a neuroprotective role for CoQ10 was shown in iron-
induced apoptosis in dopaminergic neurons [112]. Pretreatment of
neuronal cells with CoQ10 hasmaintained themitochondrialmembrane
potential during oxidative stress and reduced the mitochondrial gener-
ation of ROS [113]. In the MPTP mouse model, CoQ10 protected against
MPTP-induced dopamine depletion and the loss of dopaminergic neu-
rons in aged mice [114]. Similarly, CoQ10 protected against MPTP toxic-
ity in the chronic MPTP model, which mimics the progressive nature of
PD [114].
A combination of creatine and CoQ10 exhibited a signiﬁcant neuro-
protective effect in chronicMPTP-treatedmice [115]. Oral administration
of CoQ10 also slowed the progression of PD in a primate model of PD
[116]. Evidence from clinical trials suggests that high doses of CoQ10 are
needed for beneﬁcial results. A double-blind, placebo-controlled phase
II study of CoQ10 with three different doses, such as 300, 600 and
1200 mg daily, in 80 early untreated patients for 16 months was con-
ducted recently, resulting in a statistically improved PD rating only at
the highest dose [117]. Next, this phase II trial was extended to test a
higher dose (2400 mg/daily) of CoQ10 in early PD patients. Although a
trend emerged, the improvement in clinical scores, unfortunately, was
not statistically signiﬁcant. One possible reason could be the lower num-
ber of patients [118]. Recently, an NINDS-funded phase III, multicenter,
randomized, placebo-controlled, double-blind trial of CoQ10 at doses of
1200 and 2400 mg/daily was initiated on 600 early, non-medicated PD
patients. Hopefully, some positive outcome will come from this clinical
trial.
6.4. Urate
Urate (uric acid; Fig. 2E) plays a role in the regulation of oxidative
stress by acting as a scavenger of superoxide, hydroxyl radical, and sin-
glet oxygen and as an iron chelator [119–121]. Urate inhibits oxidative
stress and prevents dopaminergic cell death in both cell culture and an-
imal models of PD [122,123]. In humans, several prospective cohort
studies demonstrated that higher blood levels of urate were associated
with a signiﬁcantly reduced risk of developing PD [124–127]. In another
prospective study, PD patients with high urate intake progressed slower
toward the disability endpoint requiring dopamine treatment [128]. Al-
though these ﬁndings indicate that urate intake could protect individ-
uals from PD progression, the use of urate in PD treatment remains
limited because elevating urate in the serum increases the risk of gout,
a risk that is further compounded by the consumption of alcohol and
fructose [129].
6.5. Apocynin and its derivative
Apocynin (4-hydroxy-3-methoxyacetophenone; Fig. 2F) is a plant-
derived antioxidant widely used as an effective NADPH oxidase inhibi-
tor, which interferes with the assembly of cytosolic NADPH oxidase
components with the membrane components. NADPH is one of themajor sources of cellular ROS during neurodegeneration. Apocynin
protects dopaminergic neurons against MPP+-induced oxidative stress
and cell death in cell cultures [130]. In contrast, no beneﬁcial efﬁcacy
[131] or pro-oxidant property [132] of apocynin has been reported.
Apocynin can be converted to diapocynin (Fig. 2G) in vivo, which is a
more efﬁcient inhibitor of NADPH oxidase than apocynin itself [133].
Additionally, diapocynin has higher lipophilicity than apocynin [134].
Interestingly, we recently demonstrated in a mouse MPTP model of
PD, that the compound diapocynin protected against nigrostriatal dam-
age and inhibited inﬂammatory and oxidative stress processes [135]. In
LRRK2-R1441G transgenic mice, which are reported to develop PD-like
symptoms at ~10 months of age, administration of diapocynin at an oral
dose of 200 mg/kg three times per week protected against neurobehav-
ioral dysfunction [136]. These ﬁndings suggest that diapocynin can be
neuroprotective against PD, although additional animal and human
studies are needed.
In summary, although a range of antioxidant moieties has been used
with partial success in experimental cellular and animal models of PD,
no human clinical studies to date have provided conclusive evidence
of antioxidants beneﬁtting PD patients. Evidence from these clinical
trials, particularly with vitamin E, vitamin C, and creatine, is largely
inconclusive. Furthermore, clinical trials involving CoQ10 have demon-
strated that supplementationwith very high doses of CoQ10 is necessary
to show some beneﬁt in PD subjects. This may be due to the fact that
most small-molecule antioxidants get distributed throughout the
body, with only a small fraction being taken up bymitochondria. Conse-
quently, approaches selectively targeting mitochondria with antioxi-
dants have been developed.
7. Mitochondria-targeted antioxidant therapy
During the past decade, considerable progress in developing mito-
chondrially targeted antioxidants has been made. A well-established
approach is conjugation to a lipophilic cation, such as triphenylphos-
phonium (TPP) [137–139]. Phosphonium derivatives have been tradi-
tionally used to determine mitochondrial inner membrane potential.
Triphenyl-phosphonium cations consist of a positively charged phos-
phorus atom surrounded by a large hydrophobic surface (Fig. 3A),
thereby giving it the ability to directly and rapidly permeate lipid bilay-
ers while retaining the positive charge. This positive charge is used to
facilitate TPP cation accumulationwithin themitochondrialmatrix driv-
en by the large mitochondrial membrane potential (ΔΨm) of 150–
180 mV (negative inside), which was generated by the proton gradient
during the transfer of an electron to oxygen. As shown in Fig. 3B, the
plasma membrane potential (30–60 mV, negative inside) enables up
to a 10-fold accumulation of TPP in the cytoplasm. Subsequently, the
large, negative potential gradient across the mitochondrial inner mem-
brane potentiates the redistribution of TPP from the intracellular space
into the mitochondria, leading to a 100- to 500-fold higher concentra-
tion of TPP insidemitochondria [140,141]. Based on this theory,Murphy
and co-workers [139] discovered a series of orally bioavailable
mitochondria-targeted antioxidants (MTAs), includingMitoQ,MitoVitE,
andMitoTEMPOL. These compounds are known to pass through all bio-
logical membranes and accumulate within mitochondria more easily
than their non-targeted parent antioxidants, rendering them far more
effective in protecting against mitochondrial oxidative damage. This
section is dedicated to the most promising MTAs for treating neurode-
generative diseases, with emphasis on the evidence for managing PD.
7.1. MitoQ
MitoQ (mitoquinone) is the most studied and widely used antioxi-
dant targeted to mitochondria. It consists of TPP covalently attached
to the ubiquinonemoiety of the endogenous antioxidant CoQ10 through
a ten-carbon aliphatic carbon chain (Fig. 4A). Multiple lines of evidence
indicate thatMitoQpredominantly accumulateswithin themitochondria,
Fig. 3. Mitochondrial accumulation of targeted lipophilic cationic antioxidants. A, Struc-
ture of TPP (triphenylphosphonium). B, Conjugation to a lipophilic cation such as TPP spe-
ciﬁcally targets the attached bioactivemoiety (X) into themitochondrialmatrix in aΔΨm-
dependent fashion. This strategy leads to a 100–500 fold accumulation of the bioactive
compound within mitochondria. TPP, triphenylphosphonium.
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mitochondrial membrane with the ubiquinone component penetrating
deeply into the hydrophobic interior of themembrane [138]. MitoQ is a
promising neuroprotective compound due to its direct antioxidant
action. Like its parent antioxidant CoQ10, MitoQ continuously scavenges
peroxyl, peroxynitrite, and superoxide, and thus can protect mitochon-
dria against lipid peroxidation. After detoxifying oxidants, MitoQ is
recycled back to the active ubiquinol antioxidant form by the respirato-
ry chain complex II [142]. MitoQ may also display concomitant anti-
inﬂammatory and anti-hypoxic properties. Under certain conditions,
however, it may become pro-oxidant and proapoptotic due to redox
cycling of quinone and generation of superoxide [143,144]. MitoQ was
protective in a number of animal models of diseases involving oxidative
stress, including neurodegenerative diseases [145], ischemia-reperfusion
[146,147], hypertension [148], sepsis [149,150], fatty liver disease [151],
alcoholic fatty liver disease [152], and kidney damage in type I diabetes
[153].
Although the therapeutic efﬁcacy of MitoQ in PD needs to be further
conﬁrmed, several in vitro and in vivo studies have demonstrated bene-
ﬁcial effects (Table 1). When used in SH-SY5Y cells, MitoQ markedly
inhibited 6-OHDA-induced mitochondrial fragmentation [154]. In an-
other study, we recently demonstrated the neuroprotective efﬁcacy of
MitoQ both in cell culture and in a pre-clinical animal model of PD
[155]. MitoQ protected the MPP+-induced loss of neurons and neurites
in a dopaminergic cell culture model of PD. At a dose of 4 mg/kg/day,
MitoQ protected against the MPTP-induced loss of dopaminergicneurons and terminals in the nigrostriatum and it reversed both the
MPTP-induced loss of dopamine and its metabolites as well as the
MPTP-induced loss of behavioral activities [155]. Electron paramagnetic
resonance analysis revealed that MitoQ inhibited the MPTP-mediated
mitochondrial aconitase inactivation [155], suggesting that MitoQ
indeed exerts its neuroprotective action at the intended target mito-
chondria. AdministeringMitoQ at a dose up to 500 μMthrough drinking
water for 28 weeks showed no evidence of toxicity, indicating that
MitoQ can be safely administered long-term in rodents [156]. MitoQ
has now been developed as a pharmaceutical by Antipodean Pharma-
ceuticals Inc., and it has undergone phase I and II clinical trials
[157,158]. In one clinical study, MitoQ at an oral dose of 40–80 mg/kg
prevented liver damage in hepatitis C patients [157]. In contrast to
this, another recent double-blind clinical trial failed to show any beneﬁt
from the oral intake of MitoQ in slowing the clinical progression of PD
over the course of one year [158]. One explanation for the conﬂicting re-
sults, as put forward by the authors, is that MitoQ may not work for PD
clinical remission, since nearly 50% of the dopaminergic neurons and
80% of striatal dopamine have been lost by the time PD is diagnosed.
Hence, further studies are required to clarify the therapeutic effects of
MitoQ in PD subjects.
7.2. MitoVitE
MitoVitE (mitotocopherol) was the ﬁrst MTA to be discovered,
and consists of TPP conjugated to the α-tocopherol moiety of vitamin
E through a two-carbon chain (Fig. 4B). Internalized MitoVitE is
immobilized by insertion in the lipid bilayer of the mitochondrial inner
membrane. Like MitoQ, MitoVitE appears to protect mitochondria and
cells from oxidative damage by inhibiting lipid peroxidation. MitoVitE
is taken up rapidly by isolated mitochondria and cells in culture [140].
When administered tomice by intravenous injection, it rapidly accumu-
lated in the tissues most affected by mitochondrial dysfunction and
oxidative damage, including heart, brain,muscle, liver and kidney [141].
MitoVitE is protective in a number of cellular models of mito-
chondrial oxidative stress. MitoVitE was reported to reduce peroxide-
mediated oxidative stress and to maintain proteasomal function in en-
dothelial cells [159]. Likewise, another cell culture study demonstrated
that MitoVitE protected against peroxide-induced caspase activation
[160]. MitoVitE was protective against oxidative stress-induced cell
death in ﬁbroblasts from Friedrich ataxia (FRDA) patients [161]. How-
ever, it should be noted that higher levels of MitoVitE are cytotoxic in
Jurkat cells [37]. There is also in vivo evidence for the beneﬁcial effects
of MitoVitE in several animal models of human diseases. Administering
MitoVitE to rats 30 min post-induction of sepsis by pneumonia led to
protection against cardiac damage [162]. MitoVitE was reported to
decrease oxidative stress and reduce fat deposition in a mouse model
of obesity [163]. In contrast, continuous striatal infusion of MitoVitE
in rats was not protective against the hypoxia–ischemia-induced cell
death of striatal medium-spiny neurons; moreover, MitoVitE at the
higher dose of 435 μMwas neurotoxic [164]. To date, neither the efﬁca-
cy of MitoVitE in PD nor its therapeutic potential in humans has been
investigated.
7.3. MitoTEMPOL
MitoTEMPOL is another TPP+ derivative, but one with the stable pi-
peridine nitroxide radical TEMPOL (4-hydroxy-2,2,6,6,-tetramethyl-
piperidine-1-oxyl; Fig. 4C), which accepts an electron from the potent
radical scavenger hydroxylamine. MitoTEMPOL may also act as a cyto-
solic SOD mimetic, which converts superoxide molecules into water,
and is able to detoxify ferrous iron by oxidizing it to ferric iron. The con-
jugated compound also accumulated inside energized, isolated mito-
chondria [165].
MitoTEMPOL has shown beneﬁcial effects in several in vitro set-
tings of mitochondrial oxidative stress. It has been demonstrated
Fig. 4. Structures of a range of TPP-based mitochondria-targeted antioxidants, including (A) MitoQ, (B) MitoVitE, (C) MitoTEMPOL, (D) SkQ1, (E) MitoPBN, (F) MitoPeroxidase, and
(G) MitoSOD.
1288 H. Jin et al. / Biochimica et Biophysica Acta 1842 (2014) 1282–1294that MitoTEMPOL protected pancreatic β-cells against oxidative stress
[166]. In a cellular model of ischemia-reperfusion, the related amide
linked TPP, MitoTEMPO [167], partially inhibited ATP depletion-
recovery mediated mitochondrial permeability transition pore opening
and cell death [168]. In another cellular study, treatment with
MitoTEMPOL signiﬁcantly improved arteriolar endothelial function in
vessels from type 2 diabetes mellitus patients [169]. Co-administering
MitoTEMPO to rats simultaneously with angiotensin II (Ang II) infusion
signiﬁcantly protected them against Ang II-induced hypertension
[170]. In animal models of diabetes, MitoTEMPOL prevented mito-
chondrial and cytosolic ROS production in the aorta and restoredcoronary collateral growth [171]. MitoTEMPOL has not yet been tested
in animal models of PD.
7.4. “Sk” compounds
Skulachev et al. developed an alternative series of mitochondria-
targeted antioxidants, termed “SkQs”, by using plastoquinone to replace
the ubiquinone antioxidant moiety of MitoQ [172]. The compound
SkQ1, which is a TPP+ derivative conjugated with plastoquinone itself
(Fig. 4D), is the most studied “Sk” compound. SkQ1 performed as a po-
tent antioxidant in isolated mitochondria [172]. Additional cell culture
Table 1
Mitochondria-targeted antioxidants in PD models.
In vitro
Compounds Cellular models Results Referencesa
MitoQ MPP+-induced cellular model Reduced MPP+ toxicity in N27 cells and primary mesencephalic cultures [1]
6-OHDA-induced cellular model Blocked 6-OHDA-induced mitochondrial fragmentation in SH-SY5Y cells [2]
SS-20 MPP+-induced cellular model Reduced MPP+ toxicity in SN4741 cells [3]
SS-31 MPP+-induced cellular model Reduced MPP+ toxicity in SN4741 cells [3]
In vivo
Compounds Model systems Results
MitoQ MPTP mouse model Protected dopaminergic neurodegeneration, preserved striatal dopamine, and
improved motor functions
[1]
MitoApocynin MPTP mouse model Showed neuroprotection in MPTP-treated mouse [4]
SS-31 MPTP mouse model Decreased dopaminergic neuronal loss and restored dopamine levels [3]
SS-20 MPTP mouse model Decreased dopaminergic neuronal loss and restored dopamine levels [3]
Human studies
Compounds Mode systems Results
MitoQ Phase II clinical trial Showed no neuroprotective beneﬁt of taking MitoQ [5]
a References: [1] A. Ghosh, K. Chandran, S.V. Kalivendi, J. Joseph, W.E. Antholine, C.J. Hillard, A. Kanthasamy, B. Kalyanaraman, Neuroprotection by a mitochondria-targeted drug in a
Parkinson's disease model, Free radical biology & medicine, 49 (2010) 1674–1684. [2] M.E. Solesio, T.A. Prime, A. Logan, M.P. Murphy, M. Del Mar Arroyo-Jimenez, J. Jordan, M.F. Galindo,
Themitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial ﬁssion in the 6-OHDA cell model of Parkinson's disease, Biochimica et biophysica acta, 1832 (2013) 174–
182. [3] L. Yang, K. Zhao, N.Y. Calingasan, G. Luo, H.H. Szeto, M.F. Beal, Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity, Anti-
oxidants & redox signaling, 11 (2009) 2095–2104. [4] A. Ghosh, C. Hogan, A. Kanthasamy, V. Anantharam, B. Kalyanaraman, A.G. Kanthasamy, unpublished data. [5] B.J. Snow, F.L. Rolfe,
M.M. Lockhart, C.M. Frampton, J.D. O'Sullivan, V. Fung, R.A. Smith, M.P. Murphy, K.M. Taylor, A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant
MitoQ as a disease-modifying therapy in Parkinson's disease, Movement disorders: ofﬁcial journal of the Movement Disorder Society, 25 (2010) 1670–1674.
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analogs inhibited cell death induced by hydrogen peroxide [172,173].
Extensive animal studies have demonstrated beneﬁcial roles of SkQ1
and related compounds in a number of diseases associated with elevat-
ed oxidative stress [174–177], although little information regarding the
effectiveness of “Sk” compounds against PD is currently available. Nev-
ertheless, current evidence regarding “Sk” compounds is promising, and
further exploration of these antioxidants in models of PD is warranted.
7.5. Other Mito compounds
Currently, other mitochondrially targeted antioxidants incorporat-
ing the TPP function have been developed. For instance, apocynin, a
plant derived antioxidant andNADPHoxidase inhibitor, has been conju-
gated to TPP to form MitoApocynin. Recently, we observed signiﬁcant
beneﬁcial effects of MitoApocynin in a preclinical MPTP mouse model
of PD (unpublished data; Table 1). MitoPBN is a similar TPP+ derivative
with phenoxy-butyl-nitrone (Fig. 4E). The spin trap PBN was chosen
based on PBN's well-known reactivity with carbon-centered radicals
[178]. MitoPBN was rapidly taken up by mitochondria and can block the
oxygen-induced activation of uncoupled proteins [178]. MitoPeroxidase
(Fig. 4F), a TPP-based mitochondria-targeted analog of ebselen, which
has the peroxidase-like activity, was also prepared [179]. Growing evi-
dence has indicated a class of SOD mimetics with neuroprotective
effects in experimental models of PD [180–182]. Accordingly, more re-
cently, Kelso et al. developed a mitochondrially targeted macrocyclic
SOD mimetic, MitoSOD (Fig. 4G) [167]. In preliminary experiments, it
rapidly accumulated within mitochondria and possessed SOD activity.
The efﬁcacy of MitoPeroxidase, MitoPBN and MitoSOD in vivo, particu-
larly in thepreclinicalmodels of PD, however, remains to bedetermined.
7.6. SS tetrapeptides and alternative targeting approaches
To circumvent adverse effects of TPP+, alternate strategies have been
explored for effective targeting of antioxidant to mitochondria. For ex-
ample, small antioxidant molecules have been successfully targeted to
mitochondria by incorporating mitochondria-targeted peptides. TheSzeto–Schiller (SS) tetrapeptides contain an aromatic–cationic sequence
motif that speciﬁcally enables them to be delivered to mitochondria,
where they localize to the inner mitochondrial membrane with an
approximate 1000–5000-fold accumulation [183,184]. The mechanism
behind the speciﬁc mitochondrial uptake of SS peptides is not fully
clear, but it does not seem to depend on mitochondrial potential. Deliv-
ery of these peptides to tissues in vivo through intravenous, intraperito-
neal or subcutaneous injection has been documented [142]. Currently,
a number of SS tetrapeptides have been developed, of which SS-20
and SS-31 (Fig. 5A) are the most studied. Both of them comprise a
dimethyltyrosine (Dmt) residue, which reacts with a variety of free rad-
icals and inhibits lipid peroxidation [185].
In vitro studies have reported that the peptide antioxidants potent-
ly protected neurons against toxicity induced by amyloid beta (Aβ)
[186,187], herbicides [188], t-butyl hydroperoxide (tBHP) and 3-
nitropropionic acid (3NP) [184,189]. Interestingly, SS tetrapeptides
have also shown promising beneﬁts in animal models of PD (Table 1).
In the MPTP mouse model, administering SS-31 via intraperitoneal
injection protected mice against nigrostriatal dopaminergic neurode-
generation and the loss of striatal dopamine and its metabolites [190].
Surprisingly, the SS-20 peptide, which lacks the Dmt residue and thus
lacks antioxidant properties, also demonstrated signiﬁcant protection
inMPTP-treatedmice [190], suggesting that the neuroprotective actions
of SS peptides may not be attributable to the mechanism of scavenging
ROS. Hence, additional preclinical studies on SS tetrapeptides are re-
quired to develop an effective drug capable of intervening in the pro-
gression of PD in humans.
In addition to SS peptides, several novel XJB peptides, including XJB-
5-131 (Fig. 5B), have been invented. These peptides consist of an elec-
tron and ROS scavenger (4-NH2-TEMPO) conjugated to the Leu-D-
Phe-Pro-Val-Orn fragment of gramicidin S. This pentapeptide fragment
can speciﬁcally target the XJB peptides to mitochondria. XJB-5-131 im-
provedmitochondrial function and enhanced the survival of neurons in
a mouse model of Huntington's disease [191].
Another approach to targeting mitochondria with small bioactive
molecules is through a polymer based nano-carrier. This method in-
volves biodegradable poly-lactide-co-gylcolide (PLGA) nanoparticles,
Fig. 5. Structures of (A) SS peptides (SS-20 and SS-31) and (B) XJB peptide XJB-5-131.
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ever, the biological efﬁcacies of these CoQ10 nanoparticles remain to be
investigated.
8. Conclusion and perspectives
PD is a complex, multifactorial disease triggered by both genetic and
environmental factors. Substantial evidence has implicated mitochon-
drial dysfunction and oxidative damage as important components of
PD pathogenesis. This has led to the enthusiastic use of mitochondria-
targeted interventions as a tool for modulating mitochondrial function
in the prevention and treatment of PD. Within the past 15 years, a
class of compounds, referred to as mitochondria-targeted antioxidants,
has been developed by conjugating the lipophilic triphenylphosphoni-
um cation to an antioxidant moiety. These compounds have shown
some promise in experimental models of neurodegenerative diseases
against mitochondrial oxidative damage. Most notably, MitoQ and
MitoApocynin have been efﬁcacious in experimental models of PD,
supporting the concept that mitochondria-targeted interventions
would be effective in treating PD. However, a more recent, 1-year clini-
cal study failed to showa link betweenMitoQ supplementation andpre-
vention of PD progression. Althoughmany explanations for the negative
resultsmay be postulated, one reason could be that the pharmacological
effects of these Mito compounds are not completely known. For in-
stance, MitoQ can act as a pro-oxidant and promote cell death due toredox cycling and generation of the superoxide anion. Therefore, an in-
triguing perspectivewould be to ﬁne-tune the chemical biology of these
compounds to remove the undesirable effects, as well as identify new
compounds with bioactivity against mitochondrial oxidative damage.
A second reason for the lack of efﬁcacy may be that the preclinical
assessment of these compounds in animal models of PD is woefully
inadequate. Prior to entering the clinical development phase, a sub-
stantial preclinical data set should be developed to better deﬁne
neuroprotective dose–response relationships, pharmacokinetic–phar-
macodynamic correlations, therapeutic windows and optimum dosing
regimens and treatment durations. Clearly, more preclinical studies in
rodent and othermammalianmodels are necessary. Preclinical research
in this area should not be limited to the traditional MPTP models of PD.
Perhaps a more promising animal model for preclinical studies of
mitochondria-targeted antioxidants is the MitoPark mouse, which ex-
hibits spontaneous progressive PD-like pathology and behavior. Anoth-
er potential explanation for the failure ofMitoQ in the clinical trial could
be due to the heterogeneous nature of PD, which will render any single
therapeutic agent less beneﬁcial than it appeared in simpler pre-clinical
models. A more rational strategy would be to interfere at multiple
points in the mitochondrial dysfunction by combining the mechanistic
strategies offered by two or three antioxidants to achieve clinically de-
monstrable neuroprotection. Additionally, it should be noted that the
tetraphenylphosphonium-basedmethod changesmitochondrial poten-
tials, which could be associated with toxic side effects. Thus, the future
1291H. Jin et al. / Biochimica et Biophysica Acta 1842 (2014) 1282–1294of mitochondria-targeted antioxidant therapies for PD will also depend
on us developing better andmore effective strategies targetingmitochon-
dria with bioactive molecules. On the other hand, the mitochondria-
targeted peptides (SS-31 and SS-20) have been effective in the MPTP
models of PD, although their potential to treat or prevent PD needs
further investigation. Finally, delivery of antioxidants using novel
mitochondrially targeted nanomaterials may also be an attractive strat-
egy for development of diseasemodifying drugs for treatment of neuro-
degenerative diseases such as PD.Acknowledgement
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